SCHEMBL10263175

SCHEMBL10263175

COc1ccc(-c2c[nH]c3ncccc23)c(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.56
BRD4 O60885 1/20 0.55
FGFR1 P11362 1/20 0.52
FGFR4 P22455 1/20 0.52
DYRK1A Q13627 4/20 0.51
GSK3B P49841 4/20 0.49
CDK2 P24941 4/20 0.49
CDK9 P50750 3/20 0.49
ROCK2 O75116 3/20 0.49
MAP4K4 O95819 3/20 0.49
PIM1 P11309 3/20 0.49
PRKACA P17612 3/20 0.49
HIPK2 Q9H2X6 3/20 0.49
FLT3 P36888 2/20 0.49
DAPK3 O43293 1/20 0.49
PRKD3 O94806 1/20 0.49
PAK4 O96013 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CLK2 P49760 1/20 0.49
CDK7 P50613 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL858276 0.86 BRD4 (0.62) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL5429312 0.84 BRD4 (0.55) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL16719412 0.81 CDC7 (0.50) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL26176389 0.80 BRD4 (0.64) CDC7BRD4DYRK1AGSK3BCDK2
SCHEMBL3331546 0.80 DYRK1A (0.62) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL31711042 0.80 LRRK2 (0.55) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL857087 0.80 CDC7 (0.64) CDC7BRD4FGFR1FGFR4DYRK1A
SCHEMBL857148 0.78 TGFBR1 (0.57) CDC7DYRK1AGSK3BCDK2CDK9
SCHEMBL5618155 0.77 TGFBR1 (0.71) CDC7BRD4DYRK1AGSK3BCDK2
SCHEMBL16719977 0.76 BRD4 (0.53) CDC7BRD4FGFR1FGFR4DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 CDC7 161/4885BRD4 727/4885FGFR1 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.